지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.12
- 수록면
- 80 - 86 (7page)
이용수
초록· 키워드
오류제보하기
Purpose: To evaluate the progression free survival, response rate and toxicity for patients who were treated with conventional therapy combined with metronomic chemotherapy.
Methods: patients received either chemotherapy followed by maintenance metronomic chemotherapy with or without hormonal therapy or primarily treated with hormonal therapy concomitant with metronomic chemotherapy. Metronomic chemotherapy consists of cyclophosphamide 50 mg tablet daily and methotrexate 2.5 mg twice daily on days 2 and 5 weekly, continued until disease progression or development of unacceptable toxicity.
Results: after median follow up of 18 months, 40 patients were assessed. The progression free survival was 52.5% and the median time to disease progression was 10.4 months. The overall clinical benefit (complete response [CR]+partial remission [PR]+stable disease [SD]) was 52.5 % with no G3 or G4 toxicities encountered for metronomic therapy. The median time to disease progression was 12.5 months for estrogen receptor (ER)+ve, human epidermal growth factor receptor 2 (Her2)–ve (progression free survival [PFS]: 67.5%) compared to 8 months for ER+ve, Her2+ve (PFS: 10%), 9 months for ER–ve, Her2+ve (PFS: 10%) and 8 months for triple negative (PFS: 12.5%). The difference was statistically significant (P=0.018).
Conclusion: maintenance metronomic cyclophosphamide and methotrexate demonstrated efficacy and provided durable disease stabilization especially for ER positive patients. The low costs and minimal toxicity allow patients to continue treatment for several months and support its use as an additional therapeutic tool.
Methods: patients received either chemotherapy followed by maintenance metronomic chemotherapy with or without hormonal therapy or primarily treated with hormonal therapy concomitant with metronomic chemotherapy. Metronomic chemotherapy consists of cyclophosphamide 50 mg tablet daily and methotrexate 2.5 mg twice daily on days 2 and 5 weekly, continued until disease progression or development of unacceptable toxicity.
Results: after median follow up of 18 months, 40 patients were assessed. The progression free survival was 52.5% and the median time to disease progression was 10.4 months. The overall clinical benefit (complete response [CR]+partial remission [PR]+stable disease [SD]) was 52.5 % with no G3 or G4 toxicities encountered for metronomic therapy. The median time to disease progression was 12.5 months for estrogen receptor (ER)+ve, human epidermal growth factor receptor 2 (Her2)–ve (progression free survival [PFS]: 67.5%) compared to 8 months for ER+ve, Her2+ve (PFS: 10%), 9 months for ER–ve, Her2+ve (PFS: 10%) and 8 months for triple negative (PFS: 12.5%). The difference was statistically significant (P=0.018).
Conclusion: maintenance metronomic cyclophosphamide and methotrexate demonstrated efficacy and provided durable disease stabilization especially for ER positive patients. The low costs and minimal toxicity allow patients to continue treatment for several months and support its use as an additional therapeutic tool.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Prognostic Effect of Breast Cancer Subtypes in Metastatic Breast Cancer Patients
대한임상종양학회 학술대회지
2015 .02
-
Aromatase Inhibition and Capecitabine Combination as 1<sup>st</sup> or 2<sup>nd</sup> Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
The Role of Primary Tumor Surgery in Metastatic Breast Cancer
대한외과학회 학술대회 초록집
2017 .11
-
Endocrine therapy for metastatic breast cancer
대한외과학회 학술대회 초록집
2016 .11
-
The Role of Primary Tumor Surgery in De Novo Metastatic Breast Cancer Patients
대한외과학회 학술대회 초록집
2016 .11
-
A Remarkable Achievement of Local Treatment for T4c Primary Tumor in Metastatic Breast Cancer; Case Report
대한외과학회 학술대회 초록집
2022 .11
-
The Role of Neoadjuvant Chemotherapy in Patients with ER Positive and HER2 Negative Breast Cancer
대한외과학회 학술대회 초록집
2018 .11
-
Chemotherapy and Radiation Treatment for Breast Reconstruction Patients
대한외과학회 학술대회 초록집
2019 .10
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
-
Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-analysis from Randomized Clinical Trials and Propensity Score Matching of Multicentre Cohort Study
Cancer Research and Treatment
2022 .10
-
A comparative study of the clinical characteristics of breast cancer patients less than 35 years old and older patients
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .06
-
Precision medicine in breast cancer care – what a surgical oncologist should act
대한임상종양학회 학술대회지
2021 .06
-
The Clinical Status of Radiation Therapy in Korea in 2009 and 2013
Cancer Research and Treatment
2016 .01
-
Tp53 Mutation Is Linked with High 21-Gene Recurrence Score in ER+/HER2- Breast Cancer
대한외과학회 학술대회 초록집
2021 .05
-
Predictive Factors of Pathologic N2/N3 Disease in Clinical or Pathologic N1 ER+/HER2- Breast Cancer
대한외과학회 학술대회 초록집
2023 .05
-
Breast Cancer
대한외과학회 학술대회 초록집
2022 .11
-
Breast Cancer
대한외과학회 학술대회 초록집
2020 .11
-
Breast Cancer
대한외과학회 학술대회 초록집
2020 .11
-
Breast Cancer
대한외과학회 학술대회 초록집
2022 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-513-002430281